Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:
Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Main Study Arm | Experimental | The study arm all participants are enrolled into. Participants will complete hand grip strength assessments and questionnaires. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hand grip strength assessments using a dynamometer | Device | Squeeze a dynamometer with one hand to measure hand grip strength. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date | The percentage of participants with hand grip strength (HGS) test results at 6 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the 6-month follow-up assessment. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Participants with Hand Grip Strength (HGS) Measurements at Study Baseline | The percentage of participants with hand grip strength (HGS) test results at study baseline. Hand grip strength is measured in kilograms with a hand-held dynamometer. | At the time of the baseline assessment for the study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniel J Renouf, MD, MPH | Contact | 800-663-3333 | drenouf@bccancer.bc.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| BC Cancer | Vancouver | British Columbia | V5Z 4E6 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Armstrong V, Stretch C, Fitzgerald L, Gopaul A, McKinnon G, Koziak J, Kopciuk K, Brockton N, Bathe O. Characterizing cancer-associated myosteatosis: anatomic distribution and cancer-specific variability of low radiodensity muscle. JCSM Rapid Communications. 2021; 4(2):197-206. doi: 10.1002/rco2.46 | ||
| 34545711 | Background | Song M, Zhang Q, Tang M, Zhang X, Ruan G, Zhang X, Zhang K, Ge Y, Yang M, Li Q, Li X, Liu X, Li W, Cong M, Wang K, Song C, Shi H. Associations of low hand grip strength with 1 year mortality of cancer cachexia: a multicentre observational study. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1489-1500. doi: 10.1002/jcsm.12778. Epub 2021 Sep 20. | |
| 11519031 |
Not provided
Not provided
Only aggregate data will be shared with other researchers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Frequency of Participants with Hand Grip Strength (HGS) Measurements at 3 Months From Treatment Start Date |
The percentage of participants with hand grip strength (HGS) test results at 3 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer. |
| From the date anti-cancer therapy is initiated until the 3-month follow-up assessment. |
| Frequency of Participants with Hand Grip Strength (HGS) Measurements at 9 Months From Treatment Start Date | The percentage of participants with hand grip strength (HGS) test results at 9 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the 9-month follow-up assessment. |
| Frequency of Participants with Hand Grip Strength (HGS) Measurements at 12 Months From Treatment Start Date | The percentage of participants with hand grip strength (HGS) test results at 12 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the 12-month follow-up assessment. |
| Proportion of Participants with Sarcopenia Using CT Image Alone (Sarcopenia CT) | The percentage of participants at each timepoint that meet the criteria for sarcopenia using the established definitions determined by CT image alone, namely the sex- and BMI-specific cut-off points developed by Caan et al. (2017). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Proportion of Participants with Sarcopenia Using Physical Function Alone (Sarcopenia P) | The percentage of participants at each timepoint that meet the criteria for sarcopenia using the definition of the Sarcopenia Definitions and Outcomes Consortium (SDOC) (Bhasin et al. 2020). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Proportion of Participants with Sarcopenia Using a Combination of CT Image and Physical Function (Sarcopenia COMB) | The percentage of participants at each timepoint that meet the criteria for sarcopenia using the definition by the European Working Group on Sarcopenia in Older Adults (EWGSOP2) (Cruz-Jentoft et al. 2019), which is supported by the Asian Working Group for Sarcopenia (Chen et al. 2019), and the Australian and New Zealand Society for Sarcopenia and Frailty Research (Zanker et al. 2023a, Zanker et al. 2023b). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Index (SMI) | The change in hand grip strength (HGS) for each unit of increase in skeletal muscle index (SMI). Hand grip strength is measured in kilograms with a hand-held dynamometer. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Density (SMD) | The change in hand grip strength (HGS) for each unit of increase in skeletal muscle density (SMD). Hand grip strength is measured in kilograms with a hand-held dynamometer. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Gauge (SMG) | The change in hand grip strength (HGS) for each unit of increase in skeletal muscle gauge (SMG). Hand grip strength is measured in kilograms with a hand-held dynamometer. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Visceral Adipose Tissue (VAT) | The change in hand grip strength (HGS) for each unit of increase in visceral adipose tissue (VAT). Hand grip strength is measured in kilograms with a hand-held dynamometer. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Subcutaneous Adipose Tissue (SAT) | The change in hand grip strength (HGS) for each unit of increase in subcutaneous adipose tissue (SAT). Hand grip strength is measured in kilograms with a hand-held dynamometer. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Intermuscular Adipose Tissue (IMAT) | The change in hand grip strength (HGS) for each unit of increase in intermuscular adipose tissue (IMAT). Hand grip strength is measured in kilograms with a hand-held dynamometer. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Progression-Free Survival (PFS) | The change in hand grip strength (HGS) for each unit of increase in progression-free survival (PFS). Hand grip strength is measured in kilograms with a hand-held dynamometer. Progression-free survival is the length of time from the first dose of treatment until the date of clinical progression. | From the date anti-cancer therapy is initiated until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Overall Survival (OS) | The change in hand grip strength (HGS) for each unit of increase in overall survival (OS). Hand grip strength is measured in kilograms with a hand-held dynamometer. Overall survival is the length of time from the initiation of treatment that participants survive. | From the date anti-cancer therapy is initiated until the date of death or end of study, whichever comes first, assessed up to 26 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Objective Response Rate (ORR) | The change in hand grip strength (HGS) for each unit of increase in objective response rate (ORR). Hand grip strength is measured in kilograms with a hand-held dynamometer. Objective response rate is the proportion of participants who have a complete or partial response to treatment. | From the date of the baseline assessment scan until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months. |
| Difference in Hand Grip Strength (HGS) Between Treatment Regimens | The difference in the amount of hand grip strength (HGS) between participants receiving different treatment regimens. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Stage | The change in hand grip strength (HGS) for each unit of increase in tumour stage as defined by the American Joint Committee on Cancer (AJCC). Hand grip strength is measured in kilograms with a hand-held dynamometer. Tumour stage describes the extent of cancer growth and spread. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Grade | The change in hand grip strength (HGS) for each unit of increase in tumour grade as defined by a four-tier grading system. Hand grip strength is measured in kilograms with a hand-held dynamometer. Tumour grade describes the appearance of cancer cells and their expected growth rate. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Difference in Hand Grip Strength (HGS) Between Sites of Metastasis | The difference in the amount of hand grip strength (HGS) between participants with different sites of metastasis. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Hand Grip Strength (HGS) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in hand grip strength (HGS). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in hand grip strength (HGS). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Hand grip strength is measured in kilograms with a hand-held dynamometer. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle index (SMI). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle index (SMI). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm^2/m^2 and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle density (SMD). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle density (SMD). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle gauge (SMG). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle gauge (SMG). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)*cm^2/m^2. | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in visceral adipose tissue (VAT). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in visceral adipose tissue (VAT). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT) | The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT) | The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT) | The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT) | The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm^2 from CT imaging of the third lumbar vertebra (L3). | From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months. |
| Background |
| Cheville A. Rehabilitation of patients with advanced cancer. Cancer. 2001 Aug 15;92(4 Suppl):1039-48. doi: 10.1002/1097-0142(20010815)92:4+3.0.co;2-l. |
| 8433390 | Background | Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365. |
| 23797577 | Background | Wheelwright S, Darlington AS, Hopkinson JB, Fitzsimmons D, White A, Johnson CD. A systematic review of health-related quality of life instruments in patients with cancer cachexia. Support Care Cancer. 2013 Sep;21(9):2625-36. doi: 10.1007/s00520-013-1881-9. Epub 2013 Jun 25. |
| 25730723 | Background | Cella D, Stone AA. Health-related quality of life measurement in oncology: advances and opportunities. Am Psychol. 2015 Feb-Mar;70(2):175-85. doi: 10.1037/a0037821. |
| 32096923 | Background | Hagens ERC, Feenstra ML, van Egmond MA, van Laarhoven HWM, Hulshof MCCM, Boshier PR, Low DE, van Berge Henegouwen MI, Gisbertz SS. Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment. J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):756-767. doi: 10.1002/jcsm.12540. Epub 2020 Feb 25. |
| 28506965 | Background | Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, Feliciano EC, Castillo AL, Quesenberry CP, Kwan ML, Prado CM. Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1008-1015. doi: 10.1158/1055-9965.EPI-17-0200. Epub 2017 May 15. |
| 25468746 | Background | Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol. 2015 Feb;41(2):186-96. doi: 10.1016/j.ejso.2014.10.056. Epub 2014 Nov 3. |
| 32903666 | Background | Correa-de-Araujo R, Addison O, Miljkovic I, Goodpaster BH, Bergman BC, Clark RV, Elena JW, Esser KA, Ferrucci L, Harris-Love MO, Kritchevsky SB, Lorbergs A, Shepherd JA, Shulman GI, Rosen CJ. Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging. Front Physiol. 2020 Aug 7;11:963. doi: 10.3389/fphys.2020.00963. eCollection 2020. |
| 31877534 | Background | Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020 Jan;145:102839. doi: 10.1016/j.critrevonc.2019.102839. Epub 2019 Dec 20. |
| 18923576 | Background | Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006. doi: 10.1139/H08-075. |
| 23264206 | Background | Alipour S, Kennecke HF, Woods R, Lim HJ, Speers C, Brown CJ, Gill S, Renouf DJ, Cheung WY. Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer. J Gastrointest Cancer. 2013 Jun;44(2):203-10. doi: 10.1007/s12029-012-9472-4. |
| 36349684 | Background | Zanker J, Sim M, Anderson K, Balogun S, Brennan-Olsen SL, Dent E, Duque G, Girgis CM, Grossmann M, Hayes A, Henwood T, Hirani V, Inderjeeth C, Iuliano S, Keogh J, Lewis JR, Lynch GS, Pasco JA, Phu S, Reijnierse EM, Russell N, Vlietstra L, Visvanathan R, Walker T, Waters DL, Yu S, Maier AB, Daly RM, Scott D. Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand. J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):142-156. doi: 10.1002/jcsm.13115. Epub 2022 Nov 9. |
| 35159052 | Background | Cao A, Ferrucci LM, Caan BJ, Irwin ML. Effect of Exercise on Sarcopenia among Cancer Survivors: A Systematic Review. Cancers (Basel). 2022 Feb 3;14(3):786. doi: 10.3390/cancers14030786. |
| 36480154 | Background | Zanker J, Sim M, Anderson K, Balogun S, Brennan-Olsen SL, Dent E, Duque G, Girgis CM, Grossmann M, Hayes A, Henwood T, Hirani V, Inderjeeth C, Iuliano S, Keogh J, Lewis JR, Lynch GS, Pasco JA, Phu S, Reijnierse EM, Russell N, Vlietstra L, Visvanathan R, Walker T, Waters DL, Yu S, Maier AB, Daly RM, Scott D. The Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) sarcopenia diagnosis and management task force: Findings from the consumer expert Delphi process. Australas J Ageing. 2023 Mar;42(1):251-257. doi: 10.1111/ajag.13164. Epub 2022 Dec 8. |
| 32033882 | Background | Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4. |
| 32150289 | Background | Bhasin S, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA, Magaziner JM, Newman AB, Kiel DP, Cooper C, Guralnik JM, Cauley JA, Arai H, Clark BC, Landi F, Schaap LA, Pereira SL, Rooks D, Woo J, Woodhouse LJ, Binder E, Brown T, Shardell M, Xue QL, D'Agostino RB Sr, Orwig D, Gorsicki G, Correa-De-Araujo R, Cawthon PM. Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. J Am Geriatr Soc. 2020 Jul;68(7):1410-1418. doi: 10.1111/jgs.16372. Epub 2020 Mar 9. |
| 39282907 | Background | Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14. |
| 33053604 | Background | Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know? J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1413-1428. doi: 10.1002/jcsm.12633. Epub 2020 Oct 14. |
| 16174873 | Background | Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda). 2005 Oct;20:340-8. doi: 10.1152/physiol.00019.2005. |
| 21296615 | Background | Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. |
| 27843571 | Background | Vanhoutte G, van de Wiel M, Wouters K, Sels M, Bartolomeeussen L, De Keersmaecker S, Verschueren C, De Vroey V, De Wilde A, Smits E, Cheung KJ, De Clerck L, Aerts P, Baert D, Vandoninck C, Kindt S, Schelfhaut S, Vankerkhoven M, Troch A, Ceulemans L, Vandenbergh H, Leys S, Rondou T, Dewitte E, Maes K, Pauwels P, De Winter B, Van Gaal L, Ysebaert D, Peeters M. Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 2016 Oct 18;3(1):e000097. doi: 10.1136/bmjgast-2016-000097. eCollection 2016. |
| 30312372 | Background | Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. |
| 36604970 | Background | Westbury LD, Beaudart C, Bruyere O, Cauley JA, Cawthon P, Cruz-Jentoft AJ, Curtis EM, Ensrud K, Fielding RA, Johansson H, Kanis JA, Karlsson MK, Lane NE, Lengele L, Lorentzon M, McCloskey E, Mellstrom D, Newman AB, Ohlsson C, Orwoll E, Reginster JY, Ribom E, Rosengren BE, Schousboe JT, Shiroma EJ, Harvey NC, Dennison EM, Cooper C; International Musculoskeletal Ageing Network. Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts. J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):565-575. doi: 10.1002/jcsm.13160. Epub 2023 Jan 5. |
| 25071331 | Background | Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014 Jul 28;20(28):9361-73. doi: 10.3748/wjg.v20.i28.9361. |
| 31355882 | Background | Brown JC, Caan BJ, Prado CM, Cespedes Feliciano EM, Xiao J, Kroenke CH, Meyerhardt JA. The Association of Abdominal Adiposity With Mortality in Patients With Stage I-III Colorectal Cancer. J Natl Cancer Inst. 2020 Apr 1;112(4):377-383. doi: 10.1093/jnci/djz150. |
| 28881381 | Background | Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, Xiao J, Castillo AL, Caan BJ. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. Cancer. 2017 Dec 15;123(24):4868-4877. doi: 10.1002/cncr.30950. Epub 2017 Sep 7. |
| 26814378 | Background | Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016 Apr;5(4):607-16. doi: 10.1002/cam4.621. Epub 2016 Jan 27. |
| 25163434 | Background | Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim KI, Kim CH, Kim JH. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015 Mar;23(3):687-94. doi: 10.1007/s00520-014-2418-6. Epub 2014 Aug 28. |
| 26070723 | Background | Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015 Aug;6(4):489-97. doi: 10.1007/s13244-015-0414-0. Epub 2015 Jun 13. |
| 24189893 | Background | Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care. 2013 Dec;7(4):383-9. doi: 10.1097/SPC.0000000000000011. |
| 17545532 | Background | Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007 Jun 1;13(11):3264-8. doi: 10.1158/1078-0432.CCR-06-3067. |
| 37026453 | Background | Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg. 2023 Jul 1;278(1):22-30. doi: 10.1097/SLA.0000000000005878. Epub 2023 Apr 7. |
| 36483975 | Background | Lew D, Kamal F, Phan K, Randhawa K, Cornwell S, Bangolo AI, Weissman S, Pandol SJ. Epidemiologic risk factors for patients admitted with chronic pancreatitis and pancreatic ductal adenocarcinoma in the United States. World J Clin Oncol. 2022 Nov 24;13(11):907-917. doi: 10.5306/wjco.v13.i11.907. |
| ID | Term |
|---|---|
| D002100 | Cachexia |
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D015431 | Weight Loss |
| D001836 | Body Weight Changes |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D013851 | Thinness |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
Not provided
Not provided